Stockscreener 앱 받기
1.44
4.35%
0.06
시간 외 거래:
1.44
Oragenics Inc 주식(OGEN)의 최신 뉴스
Oragenics Inc. Stock Analysis and ForecastExceptional return forecasts - Autocar Professional
What analysts say about Oragenics Inc. stockOutstanding stock performance - Autocar Professional
Is Oragenics Inc. a good long term investmentPhenomenal returns - jammulinksnews.com
What drives Oragenics Inc. stock pricePhenomenal investment performance - jammulinksnews.com
Why Oragenics Inc. stock attracts strong analyst attention5x Profit Potential - Newser
Oragenics Announces Approval of Common Stock Listing on NYSE MKT - AOL.com
Oragenics Partners With Sterling For U.S.-Based Manufacturing Of Concussion Drug ONP-002 - Nasdaq
Oragenics Inc. Secures U.S. Manufacturing Partner for Concussion Drug Ahead of Phase IIb Trials - citybuzz -
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development - The Manila Times
Oragenics partners with Sterling for concussion drug production By Investing.com - Investing.com South Africa
Oragenics partners with Sterling for concussion drug production - Investing.com
What makes Oragenics Inc. stock price move sharplyHigh Probability Setups - Newser
How Oragenics Inc. stock performs during market volatilityFree Real-Time Market Predictions - Newser
Best Momentum Stock to Buy for July 7th - The Globe and Mail
Oragenics Soars 11.11% on $20M Capital Raise for Clinical Trials - AInvest
Oragenics Closes $16.5 Million Offering of Preferred Stock, Warrants - MarketScreener
Oragenics Raises $16.5M Through Public Offering - TipRanks
Oragenics, Inc. Successfully Closes $16.5 Million Public Offering of Series H Convertible Preferred Stock and Warrants - Nasdaq
Oragenics' Stock Takes A Hit With New Offering Announcement - Finimize
Form 424B5 ORAGENICS INC - StreetInsider
Oragenics Inc. Announces $20 Million Preferred Stock and Warrant Offering to Fund Concussion Trials and R&D - citybuzz -
Oragenics stock tumbles after announcing $20 million preferred stock offering - Investing.com
Why Is Oragenics Stock (OGEN) Down 55% Today? - TipRanks
Oragenics announces $20 million preferred stock offering - Investing.com Australia
Oragenics, Inc. Announces $20 Million Public Offering of Series H Convertible Preferred Stock and Warrants - Nasdaq
Oragenics announces $20 million preferred stock offering By Investing.com - Investing.com UK
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants - TradingView
Major Shareholder Odyssey Health Sells Oragenics Stock! - TipRanks
Future of Oral Probiotic Supplements | Innovations in Oral - openPR.com
Oragenics Inc. to Showcase Concussion Treatment Candidate at Major 2025 Conferences - citybuzz -
Oragenics to Present at 2025 BIO International Convention and At - GuruFocus
Oragenics, Inc. to Present ONP-002 at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium - Nasdaq
GlobeNewswire by Notified - The Manila Times
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium | OGEN Stock News - GuruFocus
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium - The Manila Times
Pre-market Movers: EVGN, WINT, CARM, UNCY... - RTTNews
Oragenics to Present at 2025 BIO International Convention - GlobeNewswire
Top stock gains: US stocks posting the highest gains today - Yahoo
4.91%
0.25%
자본화:
|
볼륨(24시간):